Stephen Chan Lam

Quick facts

Phase 2 pipeline

• Lenvatinib and Sorafenib · Oncology
  Multi-kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and other kinases.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Stephen Chan Lam portfolio CI brief
• Stephen Chan Lam pipeline updates RSS

Related

• Sector hub: All tracked pharma companies